<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int Urol Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">Int Urol Nephrol</journal-id><journal-title-group><journal-title>International Urology and Nephrology</journal-title></journal-title-group><issn pub-type="ppub">0301-1623</issn><issn pub-type="epub">1573-2584</issn><publisher><publisher-name>Springer Netherlands</publisher-name><publisher-loc>Dordrecht</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29290000</article-id><article-id pub-id-type="pmc">5845073</article-id><article-id pub-id-type="publisher-id">1776</article-id><article-id pub-id-type="doi">10.1007/s11255-017-1776-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Urology - Original Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of perioperative prophylaxis with fosfomycin tromethamine in ureteroscopic stone removal: an investigator-driven prospective, multicenter, randomized, controlled study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Qiao</surname><given-names>Lu-Dong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4129-6261</contrib-id><name><surname>Chen</surname><given-names>Shan</given-names></name><address><phone>8613611257388</phone><email>shanchentr001@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Yun-Hua</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jian-Xing</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Wei-Guo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Jian-Ping</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Liang</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0369 153X</institution-id><institution-id institution-id-type="GRID">grid.24696.3f</institution-id><institution>Department of Urology, Beijing Tongren Hospital, </institution><institution>Capital Medical University, </institution></institution-wrap>No. 1 Dongjiaominxiang, Dongcheng District, 100730 Beijing, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1761 5917</institution-id><institution-id institution-id-type="GRID">grid.411606.4</institution-id><institution>Department of Urology, </institution><institution>Beijing Anzhen Hospital, </institution></institution-wrap>Beijing, China </aff><aff id="Aff3"><label>3</label>Department of Urology, Beijing Tsinghua Changgung Hospital, Beijing, China </aff><aff id="Aff4"><label>4</label>Department of Urology, Liangxiang Hospital of Capital Medical University, Yanjing Medical College, Beijing, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.459327.e</institution-id><institution>Department of Urology, </institution><institution>Civil Aviation General Hospital, </institution></institution-wrap>Beijing, China </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>50</volume><issue>3</issue><fpage>427</fpage><lpage>432</lpage><history><date date-type="received"><day>27</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To compare efficacy, safety, and cost-effectiveness of fosfomycin tromethamine with other standard-of-care antibiotics in patients undergoing ureteroscopic lithotripsy.</p></sec><sec><title>Methods</title><p id="Par2">This study was a prospective, multicenter, randomized, controlled trial. Eligible patients scheduled for ureteroscopic lithotripsy were randomly assigned to receive either fosfomycin (fosfomycin group, <italic>N</italic>&#x000a0;=&#x000a0;101 patients) or standard-of-care antibiotic therapy as prophylaxis (control group, <italic>N</italic>&#x000a0;=&#x000a0;115 patients). The incidence of infectious complications and adverse events was analyzed between the two groups, as well as the cost&#x02013;benefit analysis.</p></sec><sec><title>Results</title><p id="Par3">The incidence of infections following lithotripsy was 3.0% in the fosfomycin group and 6.1% in the control group (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05). Only asymptomatic bacteriuria was reported in fosfomycin group. In the control group was reported asymptomatic bacteriuria (3.5%), fever (0.9%), bacteremia (0.9%), and genitourinary infection (0.9%). The rate of adverse events was very low, with no adverse event reported in the fosfomycin group and only one in the control group (forearm phlebitis). The average cost per patient of antibiotic therapy with fosfomycin was 151.45&#x000a0;&#x000b1;&#x000a0;8.62&#x000a0;yuan (22.7&#x000a0;&#x000b1;&#x000a0;1.3&#x000a0;USD), significantly lower compared to the average cost per patient of antibiotics used in the control group 305.10&#x000a0;&#x000b1;&#x000a0;245.95&#x000a0;yuan (45.7&#x000a0;&#x000b1;&#x000a0;36.9&#x000a0;USD; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001).</p></sec><sec><title>Conclusions</title><p id="Par4">Two oral doses of 3&#x000a0;g fosfomycin tromethamine showed good efficacy and safety and low cost in perioperative prophylaxis of infections following ureteroscopic stone removal.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antibiotic prophylaxis</kwd><kwd>Fosfomycin tromethamine</kwd><kwd>Ureteroscopy</kwd><kwd>Postoperative complications</kwd><kwd>Cost-effectiveness ratio</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media B.V., part of Springer Nature 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Due to crossover of antireflux barrier of the ureter, ureteroscopic procedures, including ureteroscopic stone removal, are associated with an increased risk of dissemination of pathogens from lower urinary tract to the upper tract and thus with an increased risk of post-procedure infections [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Currently, there is consensus that patients undergoing ureteroscopic stone removal should receive antibiotic prophylaxis, which has been shown to reduce the incidence of post-procedure urinary tract infections [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. While consensus exists on the need for antibiotic prophylaxis, guidelines on periprocedural prophylaxis in urological interventions recommend either fluoroquinolones or trimethoprim&#x02013;sulfamethoxazole as first-line therapy [<xref ref-type="bibr" rid="CR3">3</xref>] or to choose antibiotic regimen based on local epidemiology of drug resistance of potential pathogens [<xref ref-type="bibr" rid="CR4">4</xref>] or based on the presence of other risk factors for infection and stone localization [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par6">In China, the most frequently used antibiotics for the treatment of urinary tract infections (UTIs) and their prophylaxis post-endourologic procedures have been cephalosporins and fluoroquinolones [<xref ref-type="bibr" rid="CR7">7</xref>]. The emergence of resistant strains, including strains producing extended-spectrum &#x003b2;-lactamase (ESBL), and safety issues related to fluoroquinolones has increased the interest in finding other antibiotics that can be used in UTI prophylaxis and therapy [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Recently, fosfomycin has become an interesting alternative for treating UTIs due to the low prevalence of resistance of pathogens to this antibiotic [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par7">Although the experience with fosfomycin for treatment of UTIs is growing in China, no data are yet available on its use for prophylaxis of infections post-ureteroscopic stone removal. In this context, we aimed to assess the efficacy and safety of fosfomycin tromethamine in the prophylaxis of infectious complications post semi-rigid ureteroscopic lithotripsy.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study design and participants</title><p id="Par8">This was a prospective, multicenter, randomized, controlled trial performed between September 2015 and September 2016, in five hospitals in Beijing, China. Eligible patients were randomly assigned 1:1 to receive either fosfomycin tromethamine as preoperative prophylaxis (fosfomycin group) or other antibiotics according to local standard of practice (second-generation cephalosporin, fluoroquinolones, and other intravenous antibiotics; control group). The randomization was performed using a computer-generated list of random numbers.</p><p id="Par9">All patients underwent transurethral retrograde semi-rigid ureteroscopic lithotripsy (holmium&#x02013;YAG laser lithotripsy or pneumatic lithotripsy), and ureteral stent and catheter were routinely retained after operation. Four study visits were performed in all patients: baseline (Visit 1, before the ureteroscopic lithotripsy procedure), ureteroscopic lithotripsy procedure (Visit 2), 1&#x02013;3&#x000a0;days following the procedure (Visit 3), and 1&#x02013;4&#x000a0;weeks following the procedure (Visit 4). Patient data and characteristics, including medical history, biochemistry test results, and urine culture, were recorded at baseline. For the assessment of efficacy, urine test and urine culture were repeated at Visit 3 after catheter removal (1&#x02013;3&#x000a0;day after the procedure) and at Visit 4 after double-J stent removal (1&#x02013;4&#x000a0;week after ureteroscopic lithotripsy procedure), and body temperature was monitored. If body temperature was &#x0003e;&#x000a0;38&#x000a0;&#x000b0;C, blood culture was also performed. For the assessment of stone-free status (defined as no stone or stone fragments &#x02264;&#x000a0;4&#x000a0;mm), each patient underwent a kidney, ureter, and bladder X-ray investigation in the first day after ureteroscopic lithotripsy procedure and an urinary tract computer tomography scan before the double-J stent removal. Safety data, including assessment of kidney and liver function tests, were collected throughout the study.</p><p id="Par10">Enrolled patients had uncomplicated ureteral stone, no or mild hydronephrosis, negative nitrites, and &#x0003c;&#x000a0;5 white blood cells/high power field at urine test. Ureteral stone was to be located either in the lower or middle ureter or in the upper ureter after shock wave lithotripsy (SWL) failure or patients had residual stones after SWL. Additionally, patients with radiolucent ureteral calculus were also an indication in our group. The main exclusion criteria were: kidney stone; moderate or severe hydronephrosis; positive urine culture [&#x0003e;&#x000a0;100,000 colony-forming units/ml (CFU/ml)]; allergy to the test drug; fever (&#x02265;&#x000a0;38&#x000a0;&#x000b0;C); patients with preexisting ureteric stent or nephrostomy tube; use of immunosuppressants or medical history of immunodeficiency; liver disease with alanine transaminase and aspartate aminotransferase greater than twice the upper normal limit; renal dysfunction (creatinine level greater than 1.5 folds the upper normal limit); use of antibiotics within 72&#x000a0;h before enrollment; history of central nervous system or psychiatric disorders.</p></sec><sec id="Sec4"><title>Study treatment</title><p id="Par11">Fosfomycin group received two oral doses of 3&#x000a0;g fosfomycin tromethamine powder administered 2&#x02013;4&#x000a0;h before the ureteroscopic lithotripsy and in the morning following the procedure. Fosfomycin tromethamine was produced by Shanxi Qianyuan Pharmaceutical Co., Ltd (batch number 20150803) and was purchased locally by each participating institution. Control group received two doses of intravenous antibiotics, according to local standards&#x02014;the first one administered 0.5&#x000a0;h before the procedure and the second one in the morning following the ureteroscopic lithotripsy.</p></sec><sec id="Sec5"><title>Primary and secondary endpoints</title><p id="Par12">The primary endpoint was the incidence of infectious complications during the study, including asymptomatic bacteriuria (&#x0003e;&#x000a0;100,000&#x000a0;CFU/ml, no symptoms of infection), symptomatic UTIs (midstream voided urine culture &#x0003e;&#x000a0;10,000&#x000a0;CFU/ml with concomitant dysuria, urinary frequency, and urgency), fever (&#x0003e;&#x000a0;38&#x000a0;&#x000b0;C, excluding other infectious diseases), urosepsis, bacteremia, and genitourinary infection. Urosepsis was defined as the presence of at least 2 of the following: a temperature &#x0003e;&#x000a0;38 or &#x0003c;&#x000a0;36&#x000a0;&#x000b0;C, a pulse rate &#x0003e;&#x000a0;90 beats/min, a respiratory rate &#x0003e;&#x000a0;20 breaths/min or hypoventilation with a partial pressure of arterial carbon dioxide &#x0003c;&#x000a0;32&#x000a0;mmHg, and white blood cell count &#x0003e;&#x000a0;12,000 or &#x0003c;&#x000a0;4000 or &#x02265;&#x000a0;10% immature white blood cells [<xref ref-type="bibr" rid="CR10">10</xref>]. Genitourinary infection in men was diagnosed if epididymitis and pain and swelling of the testicles were present. The secondary endpoints included safety and cost-effectiveness analyses.</p></sec><sec id="Sec6"><title>Statistical methods</title><p id="Par13">Based on previous complication rates following endourological procedures reported in the literature [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>], we assumed that in our sample complication rates will be of around 10%. Considering a non-inferiority margin of 0.05 (5%), a probability of type I error (&#x003b1;) of 0.025, and a confidence interval of 95%, we calculated that 229 patients should be enrolled. To account for an estimated dropout rate of 5%, we decided to enroll 240 patients.</p><p id="Par14">The analysis of baseline data was to be performed in the full analysis set including all randomized patients, regardless of the number of antibiotic doses or study visits performed. Efficacy analysis was to be performed in per-protocol set (including those patients who completed the treatment originally allocated) and safety analysis in the safety analysis set (according to the treatment received and including those patients for which at least one safety assessment was performed).</p><p id="Par15">Continuous data are shown as mean&#x000a0;&#x000b1;&#x000a0;standard deviation and categorical variables as frequency. <italic>t</italic> test and Chi-square tests were used to compare data between study groups. Cost-effectiveness and sensitivity analyses were performed to assess the optimal balance between the cost and the effect of the study treatment. The cost-effectiveness ratio (<italic>C</italic>/<italic>E</italic>) represents the cost of per unit effect, with smaller values for lower costs. The sensitivity analysis was performed to evaluate the changes in the cost-effectiveness analysis when the cost varies. In this study, the cost was cut down by 10%. Data analysis was performed by using SPSS version 10.0 software. Statistical significance was defined as <italic>p</italic> &#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par16">Two hundred and forty patients were enrolled and randomized in the two study groups (120 patients in each study group); of these 24 were excluded from the analysis due to noncompliance with main inclusion criteria. Thus, 216 patients fulfilling all inclusion criteria and without exclusion criteria (101 patients in fosfomycin group and 115 in control group) were included in the analysis presented here. All patients received treatments according to study groups they were randomized in and undergone all study procedures and visits. Therefore, all study populations were identical and included 216 patients.</p><p id="Par17">Gender, age, frequency of mild preoperative hydronephrosis, stone size, and stone location were similar in the two study groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). As per inclusion criteria (urine test and urine culture), none had urinary tract infection before ureteroscopic procedure. In the control group, the most frequently prescribed antibiotics were cephamycin (35.7% of the study group) and second-generation cephalosporins (31.7%). Other antibiotics prescribed were: penicillin (14.7%), fluoroquinolones (8.7%), and third-generation cephalosporin plus &#x003b2;-lactamase inhibitors (8.7%). As procedure for ureteral stone fragmentation, YAG laser lithotripsy was used in 52 (51.5%) patients in the fosfomycin group and 58 (50.4%) patients in the control group (<italic>p</italic> for the difference between groups &#x0003e;&#x000a0;0.05). Pneumatic lithotripsy was used in 49 (48.5%) patients in the fosfomycin group and 57 (49.6%) patients in the control group (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05). The length of the procedure and the stage I stone-free rates were also similar in the study groups: length of the procedure 35.4&#x000a0;&#x000b1;&#x000a0;28.7&#x000a0;min versus 39.8&#x000a0;&#x000b1;&#x000a0;27.8&#x000a0;min (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05); stage I stone-free rates 94% versus 92%, respectively (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05). There was no statistical difference between groups in the mean time of ureteral stent removal following the procedure: 15.5&#x000a0;&#x000b1;&#x000a0;7.2&#x000a0;days in the fosfomycin group and 16.5&#x000a0;&#x000b1;&#x000a0;6.8&#x000a0;days in the control group, <italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline demographic and clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Fosfomycin group (<italic>n</italic>&#x000a0;=&#x000a0;101)</th><th align="left">Control group (<italic>n</italic>&#x000a0;=&#x000a0;115)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Age (years), mean&#x000a0;&#x000b1;&#x000a0;SD</td><td align="left">49.3&#x000a0;&#x000b1;&#x000a0;15.2</td><td align="left">47.7&#x000a0;&#x000b1;&#x000a0;13.9</td><td align="left">0.546</td></tr><tr><td align="left">Male gender, <italic>n</italic> (%)</td><td align="left">50 (49.5%)</td><td align="left">65 (56.5%)</td><td align="left">0.900</td></tr><tr><td align="left" colspan="4">Stone location, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Upper</td><td align="left">26 (25.7%)</td><td align="left">30 (26.1%)</td><td align="left" rowspan="3">0.421</td></tr><tr><td align="left">&#x000a0;Middle</td><td align="left">46 (45.5%)</td><td align="left">52 (45.2%)</td></tr><tr><td align="left">&#x000a0;Lower</td><td align="left">29 (28.7%)</td><td align="left">33 (28.7%)</td></tr><tr><td align="left" colspan="4">Stone size, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;&#x0003c;&#x000a0;0.6&#x000a0;cm</td><td align="left">12 (11.9%)</td><td align="left">15 (13.0%)</td><td align="left" rowspan="4">0.959</td></tr><tr><td align="left">&#x000a0;0.6&#x02013;0.8&#x000a0;cm</td><td align="left">36 (35.6%)</td><td align="left">42 (36.5%)</td></tr><tr><td align="left">&#x000a0;0.8&#x02013;1.2&#x000a0;cm</td><td align="left">38 (37.6%)</td><td align="left">40 (34.8%)</td></tr><tr><td align="left">&#x000a0;&#x0003e;&#x000a0;1.2&#x000a0;cm</td><td align="left">15 (14.9%)</td><td align="left">18 (15.7%)</td></tr><tr><td align="left">Mild hydronephrosis, <italic>n</italic> (%)</td><td align="left">65 (64.4%)</td><td align="left">70 (60.9%)</td><td align="left">0.990</td></tr></tbody></table><table-wrap-foot><p><italic>SD</italic> standard deviation; <italic>n</italic> (%), number (percentage) of patients</p></table-wrap-foot></table-wrap>
</p><p id="Par18">The incidence of infections following lithotripsy in all patients was 4.6% (10/216), including asymptomatic bacteriuria 3.2% (7/216), two episodes of fever in one patient 0.5% (1/216), urosepsis 0.5% (1/216), and genitourinary infection 0.5% (1/216). Per study group, only asymptomatic bacteriuria was reported in fosfomycin group (3.0% of the patients). In the control group was reported asymptomatic bacteriuria (3.5%), fever (0.9%), bacteremia (0.9%), and genitourinary infection (0.9%). There was no statistically significant difference between study groups with regard to the post-procedure infections (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The microorganisms identified in the urine culture of those with asymptomatic bacteriuria were <italic>Escherichia coli</italic> (1 patient in fosfomycin group and 2 patients in control group), <italic>Enterococcus faecalis</italic> and <italic>pseudomonas aeruginosa</italic> (1 patient in fosfomycin group), <italic>Enterococcus faecalis</italic> alone (1 patient in control group), <italic>Lactobacillus gasseri</italic> (1 patient in fosfomycin group), and <italic>Staphylococcus haemolyticus</italic> (1 patient in control group). In patients with other infectious complication, urine cultures were negative.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Efficacy analysis&#x02014;the frequency of post-surgery complications</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Overall complications, <italic>n</italic> (%)</th><th align="left">Asymptomatic bacteriuria, <italic>n</italic> (%)</th><th align="left">Symptomatic urinary tract infections, <italic>n</italic> (%)</th><th align="left">Fever, <italic>n</italic> (%)</th><th align="left">Urosepsis, <italic>n</italic> (%)</th><th align="left">Bacteremia, <italic>n</italic> (%)</th><th align="left">Genitourinary infection, <italic>n</italic> (%)</th></tr></thead><tbody><tr><td align="left">Fosfomycin group (<italic>n</italic>&#x000a0;=&#x000a0;101)</td><td align="left">3 (3.0%)</td><td align="left">3 (3.0%)</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">Control group (<italic>n</italic>&#x000a0;=&#x000a0;115)</td><td align="left">7 (6.1%)</td><td align="left">4 (3.5%)</td><td align="left">0</td><td align="left">1 (0.9%)</td><td align="left">0</td><td align="left">1 (0.9%)</td><td align="left">1 (0.9%)</td></tr><tr><td align="left"><italic>p</italic> value</td><td align="left">&#x0003e;&#x000a0;0.05</td><td align="left">&#x0003e;&#x000a0;0.05</td><td align="left">&#x02013;</td><td align="left">&#x0003e;&#x000a0;0.05</td><td align="left">&#x02013;</td><td align="left">&#x0003e;&#x000a0;0.05</td><td align="left">&#x0003e;&#x000a0;0.05</td></tr></tbody></table><table-wrap-foot><p><italic>n</italic> (%), number (percentage) of patients</p></table-wrap-foot></table-wrap>
</p><p id="Par19">One adverse drug reaction (forearm phlebitis) was reported in one patient from the control group who received cefmetazole sodium. No adverse drug reactions were reported in patients from fosfomycin group.</p><p id="Par20">The average cost of antibiotic therapy in fosfomycin group was 151.5&#x000a0;&#x000b1;&#x000a0;8.6&#x000a0;yuan (22.7&#x000a0;&#x000b1;&#x000a0;1.3&#x000a0;USD; ranging between 135.6 and 160.0&#x000a0;yuan) and in control group was 305.1&#x000a0;&#x000b1;&#x000a0;246.0&#x000a0;yuan (45.7&#x000a0;&#x000b1;&#x000a0;36.9&#x000a0;USD; ranging between 36.8 and 859.1&#x000a0;yuan; <italic>p</italic> value for difference between groups &#x0003c;&#x000a0;0.001). These costs did not include the cost of infusion set and sodium chloride solution. The cost-effectiveness ratio was 1.6 for fosfomycin group and 3.3 for control group. The result of sensitivity analysis was consistent with the cost-effectiveness result, as shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Cost-effectiveness analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Cost (yuan)</th><th align="left">Effectiveness<sup>a</sup> (%)</th><th align="left"><italic>C</italic>/<italic>E</italic></th><th align="left">&#x00394;<italic>C</italic>/&#x00394;<italic>E</italic></th></tr></thead><tbody><tr><td align="left" colspan="5">Cost-effectiveness</td></tr><tr><td align="left">&#x000a0;Fosfomycin group</td><td align="left">151.5</td><td align="left">97.0</td><td align="left">1.6</td><td align="left" rowspan="2">&#x02212;&#x000a0;49.3</td></tr><tr><td align="left">&#x000a0;Control group</td><td align="left">305.1</td><td align="left">93.9</td><td align="left">3.3</td></tr><tr><td align="left" colspan="5">Sensitivity<sup>b</sup></td></tr><tr><td align="left">&#x000a0;Fosfomycin group</td><td align="left">136.3</td><td align="left">97.0</td><td align="left">1.4</td><td align="left">&#x02212;&#x000a0;44.3</td></tr><tr><td align="left">&#x000a0;Control group</td><td align="left">274.6</td><td align="left">93.9</td><td align="left">2.9</td><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>C</italic>/<italic>E</italic>, cost-effectiveness ratio; &#x00394;<italic>C</italic>/&#x00394;<italic>E</italic>, incremental cost-effectiveness ratio</p><p><sup>a</sup>Effectiveness&#x000a0;=&#x000a0;1&#x02014;overall complication rate</p><p><sup>b</sup>Sensitivity analysis&#x000a0;=&#x000a0;10% off cost-effectiveness ratio</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec8"><title>Discussions</title><p id="Par21">In this study, two oral doses of fosfomycin tromethamine administered 2&#x02013;4&#x000a0;h before and post-ureteroscopic lithotripsy showed similar efficacy and safety with lower cost, compared with other antibiotics used as standard of care in the control group.</p><p id="Par22">The rates of post-lithotripsy infections were low (3.0% in the fosfomycin group and 6.1% in the control group) consistent with previous studies on prophylaxis of UTIs following endourological procedures, in which were reported complication rates of 1.8&#x02013;25% [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Data on the use of fosfomycin for the prophylaxis of UTIs following endourological stone removal interventions are limited. We could identify only two uncontrolled studies&#x02014;one enrolling 30 patients undergoing extracorporeal SWL and uretheroscopy and another one enrolling 60 patients (30 undergoing percutaneous nephrostomic lithotripsy) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. These studies reported good efficacy, similar to the one we observed in our patients. In one of these studies was reported significant bacteriuria in 6% of the patients [<xref ref-type="bibr" rid="CR11">11</xref>], while in the second one negative urine cultures were reported in 95% of the patients immediately after the procedure and in 85% 2&#x02013;3&#x000a0;weeks after the procedure [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par23">The rate of adverse events observed in our study groups was very low, with no adverse event reported in the fosfomycin group and only one in the control group. These results are consistent with the pooled safety analysis of 12 clinical trials in which one oral dose of 3&#x000a0;g of fosfomycin tromethamine had good tolerability, with adverse events, mainly gastrointestinal symptoms, reported in 6.1% of patients [<xref ref-type="bibr" rid="CR13">13</xref>]. Similar low rates of adverse events of 5.1% were reported in an open-label clinical study in which the efficacy of three doses of fosfomycin tromethamine was studied in Chinese population [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par24">We chose fosfomycin tromethamine as test intervention due to its bactericidal activity and broad antibacterial spectrum, with activity against both Gram-positive and Gram-negative pathogens [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. It inhibits the biogenesis of bacterial cell wall by inactivating the phosphoenolpyruvate transferase, and thus it has a unique target and rarely interacts with other antibiotics [<xref ref-type="bibr" rid="CR14">14</xref>]. Fosfomycin is also not affected by cross-resistance issues and has low toxicity and few adverse reactions [<xref ref-type="bibr" rid="CR14">14</xref>]. Fosfomycin tromethamine has excellent pharmacological properties of fosfomycin and overcomes the shortcomings of fosfomycin calcium, such as the low bioavailability and absorption rate. Previous study showed that a single oral dose of 3&#x000a0;g fosfomycin tromethamine reaches a peak urine concentration within 4&#x000a0;h and a urine concentration &#x0003e;&#x000a0;128&#x000a0;mg/L is maintained for 24&#x02013;48&#x000a0;h which is enough to suppress many kinds of uropathogens [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par25">In our study, we found several antibiotics used in the perioperative prophylaxis in the control group. Cephamycins were ranked first, and second-generation cephalosporins and penicillins antimicrobial second. Additionally, fluoroquinolones were chosen by urological surgeons in 8.7% of the patients in the control group. Although all antibiotics used in this study were effective, previous studies performed in China showed that antibiotic resistance of <italic>E. coli</italic> clinical isolates to fluoroquinolones and cephalosporins is on the rise [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>], suggesting limited efficacy of these. Both cephalosporins and fluoroquinolones remain the most commonly used antibiotics in China, due to their inclusion in the current guidelines and due to consensus that some antibiotics can be used for prophylaxis despite increasing resistance rates to preserve the sensitivity to other antibiotics used in the therapy. Meanwhile, no increases in <italic>E. coli</italic> strains resistance to fosfomycin have been reported [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In China, fosfomycin tromethamine has been shown to have good antibacterial activity against both ESBL producing and ESBL-negative <italic>E. coli</italic>, with resistance rates of 4.3 and 0%, and bacterial sensitivity rates of 87.0 and 95.1%, respectively [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par26">The cost analysis showed that the average cost per patient of antibiotic therapy with fosfomycin was 22.7&#x000a0;USD, significantly lower compared to the average cost per patient of other antibiotic drugs used (45.7&#x000a0;USD). Additionally, the cost-effectiveness ratio was significantly lower for fosfomycin group (1.6) than for control group (3.3).</p><p id="Par27">A limitation of our study was the heterogenic group of antibiotics used as control. As currently there is no consensus on which antibiotic should be used in ureteroscopic procedures as prophylaxis, we also used this study to evaluate the current state of antibiotics used in the urological infections in China.</p><p id="Par28">In conclusion, this is the first multicenter study to evaluate the perioperative prophylaxis with fosfomycin tromethamine in ureteroscopic stone removal by comparison with standard-of-care intravenous antibiotics in China, suggesting this regimen is safe and has good efficacy. Fosfomycin&#x02019;s low local cost as compared to other antibiotics combined with increasing local resistance to other antibiotics makes fosfomycin a highly attractive and cost-effective option for the prophylaxis of infections following endourological procedures. Fosfomycin may represent a valid alternative to cephalosporin and fluoroquinolones for prophylactic purposes and thus may help preventing further increase in the resistance to these antibiotics. We believe that our study can be informative for physicians in their decision-making in the perioperative prophylaxis in ureteroscopic stone removal.
</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank all study participants and the general practitioners, study nurses, and personnel who contributed to this study. The authors of the manuscript would like to acknowledge the editorial support provided by Adriana Rusu (on behalf of BC-BIOSTAT Co., Ltd) in the development of the current manuscript.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contribution</title><p>Shan Chen and Ludong Qiao contributed project development and manuscript writing/editing and interpreted the results. Yunhua Lin, Jianxing Li, Weiguo Hu, Jianping Hou, and Liang Cui contributed to data collection and manuscript writing/editing. Ludong Qiao contributed to data collection, statistical analysis, and manuscript writing/editing</p></notes><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p id="Par29">The authors declare that they have no conflict of interest.</p></sec><sec id="FPar2"><title>Ethical approval</title><p id="Par30">All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study protocol and all study documents were approved by the Ethics Committee of Beijing Tongren Hospital Capital Medical University.</p></sec><sec id="FPar3"><title>Informed consent</title><p id="Par31">Informed consent was obtained from all individual participants included in the study.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knopf</surname><given-names>HJ</given-names></name><name><surname>Graff</surname><given-names>HJ</given-names></name><name><surname>Schulze</surname><given-names>H</given-names></name></person-group><article-title>Perioperative antibiotic prophylaxis in ureteroscopic stone removal</article-title><source>Eur Urol</source><year>2003</year><volume>44</volume><fpage>115</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/S0302-2838(03)00189-1</pub-id><pub-id pub-id-type="pmid">12814685</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabe</surname><given-names>M</given-names></name></person-group><article-title>Controversies in antibiotic prophylaxis in urology</article-title><source>Int J Antimicrob Agents</source><year>2004</year><volume>23</volume><issue>Suppl 1</issue><fpage>S17</fpage><lpage>S23</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2003.09.005</pub-id><pub-id pub-id-type="pmid">15037324</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>JS</given-names><suffix>Jr</suffix></name><name><surname>Bennett</surname><given-names>CJ</given-names></name><name><surname>Dmochowski</surname><given-names>RR</given-names></name><name><surname>Hollenbeck</surname><given-names>BK</given-names></name><name><surname>Pearle</surname><given-names>MS</given-names></name><name><surname>Schaeffer</surname><given-names>AJ</given-names></name><collab>Urologic Surgery Antimicrobial Prophylaxis Best Practice Policy P</collab></person-group><article-title>Best practice policy statement on urologic surgery antimicrobial prophylaxis</article-title><source>J Urol</source><year>2008</year><volume>179</volume><fpage>1379</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2008.01.068</pub-id><pub-id pub-id-type="pmid">18280509</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mrkobrada</surname><given-names>M</given-names></name><name><surname>Ying</surname><given-names>I</given-names></name><name><surname>Mokrycke</surname><given-names>S</given-names></name><name><surname>Dresser</surname><given-names>G</given-names></name><name><surname>Elsayed</surname><given-names>S</given-names></name><name><surname>Bathini</surname><given-names>V</given-names></name><name><surname>Boyce</surname><given-names>E</given-names></name><name><surname>Luke</surname><given-names>P</given-names></name></person-group><article-title>CUA Guidelines on antibiotic prophylaxis for urologic procedures</article-title><source>Can Urol Assoc J</source><year>2015</year><volume>9</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.5489/cuaj.2382</pub-id><pub-id pub-id-type="pmid">25737749</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">T&#x000fc;rk C, Neisius A, Petrik A, Seitz C, Skolarikos A, Tepeler A, Thomas K (2017) Urolithiasis. <ext-link ext-link-type="uri" xlink:href="http://uroweb.org/guideline/urolithiasis/">http://uroweb.org/guideline/urolithiasis/</ext-link>. Accessed 25 Aug 2017</mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Bonkat G, Pickard R, Bartoletti R, Bruy&#x000e8;re F, Geerlings S, Wagenlehner F, Wullt B (2017) Urological Infections. <ext-link ext-link-type="uri" xlink:href="http://uroweb.org/guideline/urological-infections/">http://uroweb.org/guideline/urological-infections/</ext-link>. Accessed 25 Aug 2017</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name></person-group><article-title>In vitro susceptibility of Escherichia coli strains isolated from urine samples obtained in mainland China to fosfomycin trometamol and other antibiotics: a 9-year surveillance study (2004&#x02013;2012)</article-title><source>BMC Infect Dis</source><year>2014</year><volume>14</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-14-66</pub-id><pub-id pub-id-type="pmid">24502648</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>LD</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>HF</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>YJ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>BK</given-names></name><name><surname>Yang</surname><given-names>WM</given-names></name><name><surname>Zhao</surname><given-names>XK</given-names></name><name><surname>Gao</surname><given-names>XF</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study</article-title><source>BMJ Open</source><year>2013</year><volume>3</volume><fpage>e004157</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2013-004157</pub-id><pub-id pub-id-type="pmid">24309172</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kranz</surname><given-names>J</given-names></name><name><surname>Helbig</surname><given-names>S</given-names></name><name><surname>Mandraka</surname><given-names>F</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Naber</surname><given-names>KG</given-names></name></person-group><article-title>The revival of old antibiotics for treatment of uncomplicated urinary tract infections in the era of antibiotic stewardship</article-title><source>Curr Opin Urol</source><year>2017</year><volume>27</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1097/MOU.0000000000000365</pub-id><pub-id pub-id-type="pmid">27875349</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>LD</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>XF</given-names></name><name><surname>Yang</surname><given-names>WM</given-names></name><name><surname>Niu</surname><given-names>YJ</given-names></name><name><surname>Kong</surname><given-names>CZ</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>XF</given-names></name><name><surname>Shi</surname><given-names>BK</given-names></name><name><surname>Na</surname><given-names>YQ</given-names></name><name><surname>Zhang</surname><given-names>XD</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>A multi-center, controlled, randomized, open-label clinical study of levofloxacin for preventing infection during the perioperative period of ultrasound-guided transrectal prostate biopsy</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2016</year><volume>35</volume><fpage>1877</fpage><lpage>1881</lpage><pub-id pub-id-type="doi">10.1007/s10096-016-2742-5</pub-id><pub-id pub-id-type="pmid">27530532</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>di Silverio</surname><given-names>F</given-names></name><name><surname>Ferrone</surname><given-names>G</given-names></name><name><surname>Carati</surname><given-names>L</given-names></name></person-group><article-title>Prophylactic chemotherapy with fosfomycin trometamol during transurethral surgery and urological manoeuvres. Results of a multicentre study</article-title><source>Infection</source><year>1990</year><volume>18</volume><issue>Suppl 2</issue><fpage>S98</fpage><lpage>S102</lpage><pub-id pub-id-type="doi">10.1007/BF01643436</pub-id><pub-id pub-id-type="pmid">2286470</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szopinski</surname><given-names>T</given-names></name><name><surname>Antoniewicz</surname><given-names>A</given-names></name><name><surname>Bor&#x000f3;wka</surname><given-names>A</given-names></name></person-group><article-title>The prophylactic use of phosphomycin in endoscopic procedures associated urinary tract infections</article-title><source>Urol Pol</source><year>2002</year><volume>55</volume><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naber</surname><given-names>KG</given-names></name></person-group><article-title>Fosfomycin trometamol in treatment of uncomplicated lower urinary tract infections in adult women&#x02014;an overview</article-title><source>Infection</source><year>1992</year><volume>20</volume><issue>Suppl 4</issue><fpage>S310</fpage><lpage>S312</lpage><pub-id pub-id-type="doi">10.1007/BF01710021</pub-id><pub-id pub-id-type="pmid">1294524</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>SS</given-names></name><name><surname>Balfour</surname><given-names>JA</given-names></name><name><surname>Bryson</surname><given-names>HM</given-names></name></person-group><article-title>Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections</article-title><source>Drugs</source><year>1997</year><volume>53</volume><fpage>637</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.2165/00003495-199753040-00007</pub-id><pub-id pub-id-type="pmid">9098664</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussos</surname><given-names>N</given-names></name><name><surname>Karageorgopoulos</surname><given-names>DE</given-names></name><name><surname>Samonis</surname><given-names>G</given-names></name><name><surname>Falagas</surname><given-names>ME</given-names></name></person-group><article-title>Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections</article-title><source>Int J Antimicrob Agents</source><year>2009</year><volume>34</volume><fpage>506</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2009.08.013</pub-id><pub-id pub-id-type="pmid">19828298</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falagas</surname><given-names>ME</given-names></name><name><surname>Roussos</surname><given-names>N</given-names></name><name><surname>Gkegkes</surname><given-names>ID</given-names></name><name><surname>Rafailidis</surname><given-names>PI</given-names></name><name><surname>Karageorgopoulos</surname><given-names>DE</given-names></name></person-group><article-title>Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies</article-title><source>Expert Opin Investig Drugs</source><year>2009</year><volume>18</volume><fpage>921</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1517/13543780902967624</pub-id><pub-id pub-id-type="pmid">19548851</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>LD</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Guo</surname><given-names>HF</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>YJ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>BK</given-names></name><name><surname>Yang</surname><given-names>WM</given-names></name><name><surname>Zhao</surname><given-names>XK</given-names></name><name><surname>Gao</surname><given-names>XF</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name></person-group><article-title>Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study</article-title><source>BMJ Open</source><year>2013</year><volume>3</volume><fpage>e004152</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2013-004152</pub-id><pub-id pub-id-type="pmid">24334199</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Net</surname><given-names>MOHNARI</given-names></name></person-group><article-title>Bacterial resistance surveillance in China: a report from Mohnarin 2004&#x02013;2005</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2008</year><volume>27</volume><fpage>697</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1007/s10096-008-0494-6</pub-id><pub-id pub-id-type="pmid">18563461</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name></person-group><article-title>Mohnarin 2009 annual report: bacterial resistances in women urine tract infections</article-title><source>Chin J Clin Pharmacol</source><year>2011</year><volume>5</volume><fpage>352</fpage><lpage>356</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pullukcu</surname><given-names>H</given-names></name><name><surname>Aydemir</surname><given-names>S</given-names></name><name><surname>Tasbakan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Is there a rise in resistance rates to fosfomycin and other commonly used antibiotics in Escherichia coli-mediated urinary tract infections? A perspective for 2004&#x02013;2011</article-title><source>Turk J Med Sci</source><year>2013</year><volume>43</volume><fpage>537</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.3906/sag-1210-75</pub-id></element-citation></ref></ref-list></back></article>